| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | ||||||||||||
46,840 | 42,294 | 40,122 | 39,807 | 39,498 | 42,237 | 44,033 | 47,267 | 48,047 | 45,987 | 27,428 | 23,850 | 24,197 |
Costs, Expenses and Other | ||||||||||||
Cost of sales | ||||||||||||
14,112 | 13,509 | 12,912 | 14,030 | 14,934 | 16,768 | 16,954 | 16,446 | 16,871 | 18,396 | 9,019 | 5,583 | 6,140 |
Selling, general and administrative | ||||||||||||
10,615 | 10,102 | 10,074 | 10,017 | 10,313 | 11,606 | 11,911 | 12,776 | 13,733 | 13,125 | 8,543 | 7,377 | 7,556 |
Research and development | ||||||||||||
9,872 | 9,752 | 10,339 | 10,261 | 6,704 | 7,180 | 7,503 | 8,168 | 8,467 | 11,111 | 5,845 | 4,805 | 4,882 |
Restructuring costs | ||||||||||||
638 | 632 | 776 | 651 | 619 | 1,013 | 1,709 | 664 | 1,306 | 985 | 1,634 | 1,033 | 327 |
Equity income from affiliates | ||||||||||||
- | - | - | - | - | - | - | 642 | 610 | 587 | 2,235 | 2,561 | 2,976 |
U.S. Vioxx Settlement Agreement charge | ||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | -4,850 |
Other (income) expense, net | ||||||||||||
-139 | 402 | 500 | -189 | -1,527 | 11,613 | -411 | -1,116 | -946 | -1,304 | 10,668 | 2,318 | 75 |
Total Costs, Expenses and Other | ||||||||||||
35,376 | 33,593 | 33,601 | 35,148 | 34,097 | 24,954 | 38,488 | 38,528 | 40,713 | 44,334 | 12,138 | 13,919 | 20,705 |
Income Before Taxes | ||||||||||||
11,464 | 8,701 | 6,521 | 4,659 | 5,401 | 17,283 | 5,545 | 8,739 | 7,334 | 1,653 | 15,290 | 9,931 | 3,492 |
Taxes on Income | ||||||||||||
1,687 | 2,508 | 4,103 | 718 | 942 | 5,349 | 1,028 | 2,440 | 942 | 671 | 2,268 | 1,999 | 95 |
Net Income | ||||||||||||
9,777 | 6,193 | 2,418 | 3,941 | 4,459 | 11,934 | 4,517 | 6,299 | 6,392 | 982 | 13,022 | 7,932 | 3,396 |
Less: Net Loss Attributable to Noncontrolling Interests | ||||||||||||
-66 | -27 | 24 | 21 | 17 | 14 | 113 | 131 | 120 | 121 | 123 | 124 | 121 |
Net Income (Loss) Attributable to Parent | ||||||||||||
9,843 | 6,220 | 2,394 | 3,920 | 4,442 | 11,920 | 4,404 | 6,168 | 6,272 | 861 | 12,899 | 7,808 | 3,275 |
Preferred Stock Dividends | ||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | 0 |
Net Income Available to Common Shareholders | ||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | 3,275 |
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) | ||||||||||||
3.84 | 2.34 | 0.88 | 1.42 | 1.58 | 4.12 | 1.49 | 2.03 | 2.04 | 0.28 | 5.67 | 3.65 | 1.51 |
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) | ||||||||||||
3.81 | 2.32 | 0.87 | 1.41 | 1.56 | 4.07 | 1.47 | 2.00 | 2.02 | 0.28 | 5.65 | 3.63 | 1.49 |